Vaccinex, Inc. (VCNX)

4d ago, source: Yahoo Finance

On February 6, 2024, the firm acquired 1,631,648 shares of Vaccinex Inc, marking a new holding in its investment portfolio. The shares were purchased at a price of $0.5863 each, reflecting a ...

Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

1mon ago, source: Business Insider

ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company ...

Vaccinex Reports 2023 Financial Results and Provides Corporate Update

27d ago, source: Business Insider

About Vaccinex Inc. Vaccinex, Inc. is pioneering a differentiated approach to treating slowly progressive neurodegenerative diseases and cancer through the inhibition of semaphorin 4D (SEMA4D).

Vaccinex, Inc. (VCNX) Interactive Stock Chart - Yahoo Finance

1mon ago, source: Yahoo Finance

Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D ...

VCNX Stock Earnings: Vaccinex Reported Results for Q4 2023

on MSN ago, source:

Vaccinex (NASDAQ:VCNX) just reported results for the fourth quarter of 2023. Vaccinex reported earnings per share of -33 ...

Vaccinex Inc VCNX

10d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Vaccinex Reports 2023 Financial Results and Provides Corporate Update

27d ago, source: Stockhouse

ROCHESTER, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and ...